Cyclopharm Limited (ASX:CYC)

Market Cap	111.14M
Revenue (ttm)	27.57M
Net Income (ttm)	-13.20M
Shares Out	111.14M
EPS (ttm)	-0.13
PE Ratio	n/a
Forward PE	170.24
Dividend	n/a
Ex-Dividend Date	n/a

Volume	83,006
Average Volume	84,978
Open	1.000
Previous Close	1.000
Day's Range	0.990 - 1.005
52-Week Range	0.990 - 2.500
Beta	0.73
RSI	34.03
Earnings Date	May 26, 2025

About Cyclopharm

Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. The company operates Technegas which offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. It is also involved in the research and development; and distribution of third-party products to the diagnostic imaging sector. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 ...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 1986
• Employees: 95
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CYC

Financial Performance

In 2024, Cyclopharm's revenue was 27.57 million, an increase of 4.68% compared to the previous year's 26.34 million. Losses were -13.20 million, 180.8% more than in 2023.